We are live on ! Find out more
GTHX

G1 Therapeutics, Inc. Common Stock
GTHX

Delisted

GTHX was delisted on the 17th of September, 2024.

Back to rankings

104 hedge funds and large institutions have $287M invested in G1 Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 42 increasing their positions, 18 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

193% more capital invested

Capital invested by funds: $98.2M → $287M (+$189M)

133% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 18

110% more call options, than puts

Call options by funds: $1.42M | Put options by funds: $676K

39% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 18

6% more funds holding

Funds holding: 98 → 104 (+6)

Holders
104
Holders Change
+6
Holders Change %
+6.12%
% of All Funds
1.79%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
42
Reduced
18
Closed
18
Calls
$1.42M
Puts
$676K
Net Calls
+$746K
Net Calls Change
+$444K

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$16.9M
2
PBA
Paradigm Biocapital Advisors
New York
+$10.1M
3
Fisher Asset Management
Fisher Asset Management
Washington
+$7.16M
4
Millennium Management
Millennium Management
New York
+$5.08M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$3.95M

Top Sellers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
-$17.4M
2
CA
CHI Advisors
New York
-$5.06M
3
Renaissance Technologies
Renaissance Technologies
New York
-$4.13M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$3.47M
5
Citadel Advisors
Citadel Advisors
Florida
-$2.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
EI
26
EAM Investors
California
$2.79M +$2.56M +223,654 New
Charles Schwab
27
Charles Schwab
California
$2.26M +$292K +25,576 +16%
Susquehanna International Group
28
Susquehanna International Group
Pennsylvania
$2.17M +$1.25M +109,034 +168%
Rafferty Asset Management
29
Rafferty Asset Management
New York
$1.72M +$1.57M +137,472 New
NIM
30
Needham Investment Management
New York
$1.67M – – –
EGI
31
EAM Global Investors
California
$1.66M +$1.52M +133,203 New
Citigroup
32
Citigroup
New York
$1.59M +$1.44M +126,097 +10,404%
Ameriprise
33
Ameriprise
Minnesota
$1.47M +$55.6K +4,866 +4%
OQS
34
Occudo Quantitative Strategies
Florida
$1.45M +$1.33M +116,303 New
Barclays
35
Barclays
United Kingdom
$1.42M +$1.3M +113,631 New
Invesco
36
Invesco
Georgia
$1.41M +$1.29M +113,061 New
Jacobs Levy Equity Management
37
Jacobs Levy Equity Management
New Jersey
$1.28M -$3.47M -303,546 -75%
Renaissance Technologies
38
Renaissance Technologies
New York
$1.28M -$4.13M -361,600 -78%
Wellington Management Group
39
Wellington Management Group
Massachusetts
$1.27M +$226K +19,794 +24%
Citadel Advisors
40
Citadel Advisors
Florida
$1.26M -$2.64M -230,806 -70%
D.E. Shaw & Co
41
D.E. Shaw & Co
New York
$1.19M -$480K -42,005 -31%
GCM
42
Graham Capital Management
Connecticut
$1.18M +$1.08M +94,340 New
Northern Trust
43
Northern Trust
Illinois
$1.16M +$12.4K +1,084 +1%
SSA
44
Schonfeld Strategic Advisors
New York
$1.14M +$1.05M +91,523 New
Qube Research & Technologies (QRT)
45
Qube Research & Technologies (QRT)
United Kingdom
$1.14M +$288K +25,171 +38%
Connor, Clark & Lunn Investment Management (CC&L)
46
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.13M +$577K +50,481 +127%
Tudor Investment Corp
47
Tudor Investment Corp
Connecticut
$1.05M +$447K +39,155 +87%
Jane Street
48
Jane Street
New York
$1.02M +$667K +58,383 +251%
ECM
49
ExodusPoint Capital Management
New York
$986K +$775K +67,870 +613%
TI
50
Trexquant Investment
Connecticut
$840K +$561K +49,122 +270%
1
2
3 4 5

GTHX Hedge Fund Activity: Q3 2022 in Review

104 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q3 2022, worth a combined $287M — up 193% from $98.2M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new GTHX positions and 18 closed out — a net gain of 7 holders — while 42 added to existing stakes and 18 trimmed.

The largest buyer was State Street, adding an estimated $16.9M. The largest seller was Woodline Partners, cutting an estimated $17.4M.

  • 104 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q3 2022, up from 98 in Q2 2022.
  • Funds reported $287M of G1 Therapeutics, Inc. Common Stock stock for Q3 2022, up 193% quarter-over-quarter.
  • 25 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q3 2022 and 18 closed out, a net change of +7 holders.
  • The largest G1 Therapeutics, Inc. Common Stock buyer in Q3 2022 was State Street, an estimated $16.9M added.
  • The largest G1 Therapeutics, Inc. Common Stock seller in Q3 2022 was Woodline Partners, an estimated $17.4M sold.

Based on aggregated 13F filings for Q3 2022.